Effects of chronic neuroleptic treatments on nutrient selection, body weight, and body composition in the male rat under dietary self-selection.
New antipsychotic drugs often increase weight and produce metabolic disturbances in treated patients. However, the mechanisms by which neuroleptics induce these undesirable side effects in humans are not known. Studies have shown that antipsychotics can increase body weight in female but not in male rats. However, no studies investigated changes in macronutrient selection during chronic treatments with antipsychotics in male rats, and no studies investigated precisely body composition after such treatments. In the present work, we studied in male rats the effects of long-term administration of two neuroleptics: haloperidol, a classical neuroleptic which has a moderate effect on weight gain in humans, and olanzapine, an atypical neuroleptic which has a more important effect on weight gain. Treatments (both 1 mg/kg) were given orally for 6 weeks, and the animals were allowed to self-select food among carbohydrates, lipids and proteins. Food selection was measured throughout the study, and body composition was measured by dissection and weighing of the main organs and tissues. Circulating leptin, insulin and glucose were also assayed at the end of the study on blood collected at the time of carcass analysis. The results show that none of the neuroleptic treatments modified caloric intake, food selection, body weight, and body composition. Olanzapine produced a statistically non-significant increase in subcutaneous fat tissue. It is concluded that a 6-week olanzapine or haloperidol treatment in male rats under dietary macronutrient selection does not significantly affect energy regulation.
Minet-Ringuet
Julie
J
Laboratoire de Psychopharmacologie, Centre Hospitalier Paul Guiraud, Villejuif, France.
Even
Patrick C
PC
Guesdon
Benjamin
B
Tomé
Daniel
D
de Beaurepaire
Renaud
R
D000273:Adipose Tissue / Q000187:drug effects; D000818:Animals; D014150:Antipsychotic Agents / Q000008:administration & dosage*; D001522:Behavior, Animal; D001569:Benzodiazepines / Q000008:administration & dosage; D001786:Blood Glucose / Q000187:drug effects; D001823:Body Composition / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects*; D004032:Diet; D004044:Dietary Proteins / Q000008:administration & dosage; D004435:Eating / Q000187:drug effects; D002149:Energy Intake / Q000187:drug effects; D005518:Food Preferences; D006220:Haloperidol / Q000008:administration & dosage*; D008297:Male; D009752:Nutritional Status / Q000187:drug effects; D000077152:Olanzapine; D010949:Plasma / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors
D014150:Antipsychotic Agents; D001786:Blood Glucose; D004044:Dietary Proteins; D001569:Benzodiazepines; D006220:Haloperidol; D000077152:Olanzapine